Wnt signaling pathway in non-small cell lung cancer

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Stewart, David J ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; CISPLATIN; DICKKOPF 1 PROTEIN; DISHEVELLED 1; DISHEVELLED 2; DISHEVELLED PROTEIN; DOCETAXEL; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA; MICRORNA 487B; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 3; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; TANKYRASE; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR EMX2; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN; WNT11 PROTEIN; WNT7A PROTEIN; CADHERIN; WNT7A PROTEIN, HUMAN;

CANCER CELL CULTURE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL DEDIFFERENTIATION; CELL PROLIFERATION; DOWN REGULATION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; WNT SIGNALING PATHWAY; APOPTOSIS; CANCER STAGING; DNA METHYLATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; BETA CATENIN; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84892634758     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt356     Document Type: Review

References (138)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON, Canada: Canadian Cancer Society; 2013.
4. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75(3):173-234.
5. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16(12):3153-3162.
6. Teng Y, Wang X, Wang Y, Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Comm. 2010;392(3):373-379.
7. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222(1):1-10.
8. Li C, Chen H, Hu L, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol. 2008;9:11.
9. Kojima T, Shimazui T, Hinotsu S, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene. 2009;28(2):297-305.
10. Yang ZQ, Zhao Y, Liu Y, et al. Downregulation of HDPR1 is associated with poor prognosis and affects expression levels of p120-catenin and beta-catenin in nonsmall cell lung cancer. Mol Carcinog. 2010;49(5):508-519.
11. van Tienen FH, Laeremans H, van der Kallen CJ, Smeets HJ. Wnt5b stimulates adipogenesis by activating PPARgamma, and inhibiting the beta-catenin dependent Wnt signaling pathway together with Wnt5a. Biochem Biophys Res Comm. 2009;387(1):207-211.
12. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol. 2003;162(5):899-908.
13. Ren J, Wang R, Huang G, Song H, Chen Y, Chen L. sFRP1 inhibits epithelial-mesenchymal transition in A549 human lung adenocarcinoma cell line. Cancer Biother Radiopharm. 2013;28(7):565-571.
14. Vaughan AE, Halbert CL, Wootton SK, Miller AD. Lung cancer in mice induced by the jaagsiekte sheep retrovirus envelope protein is not maintained by rare cancer stem cells, but tumorigenicity does correlate with Wnt pathway activation. Mol Cancer Res. 2012;10(1):86-95.
15. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, et al. Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PloS One. 2006 (December 20);1:e93.
16. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene. 2010;29(25):3650-3664.
17. Lee S, Kang J, Cho M, et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol. 2009;34(1):161-172.
18. Pacheco-Pinedo EC, Durham AC, Stewart KM, et al. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011;121(5):1935-1945.
19. Gunther EJ, Moody SE, Belka GK, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003;17(4):488-501.
20. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 2008;29(5):895-904.
21. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia. 2004;6(1):7-14.
22. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 2009;28(21):2163-2172.
23. Lemjabbar-Alaoui H, van Zante A, Singer MS, et al. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene. 2010;29(5):635-646.
24. Gao W, Xu J, Liu L, Shen H, Zeng H, Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother. 2012;66(1):21-28.
25. Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481(7379):85-89.
26. Nakashima T, Liu D, Nakano J, et al. Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients. Oncol Rep. 2008;19(1):203-209.
27. Wang Q, Zhan P, Yu L, Song Y. [The correlation between the expression of Wnt1 and prognosis in resected non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2010;13(6):586-590.
28. Xu X, Sun PL, Li JZ, Jheon S, Lee CT, Chung JH. Aberrant Wnt1/betacatenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol. 2011;6(4):716-724.
29. Nakashima N, Huang CL, Liu D, Ueno M, Yokomise H. Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer. Int J Oncol. 2010;37(3):687-694.
30. Huang CL, Liu D, Ishikawa S, et al. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer. 2008;44(17):2680-2688.
31. Shapiro M, Akiri G, Chin C, et al. Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg. 2013;257(3):548-554.
32. Lee JS, Hur MW, Lee SK, Choi WI, Kwon YG, Yun CO. A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer. PloS One. 2012;7(5):e36520.
33. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004;23(36):6170-6174.
34. Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H. Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer. 2012;76(2):228-234.
35. Bartis D, Csongei V, Weich A, et al. Down-regulation of canonical and upregulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma. PloS One. 2013;8(3):e57393.
36. Bravo DT, Yang YL, Kuchenbecker K, et al. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer. 2013;13(1):316.
37. Liu D, Kadota K, Ueno M, Nakashima N, Yokomise H, Huang CL. Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours. Eur J Cancer. 2012;48(8):1208-1218.
38. Huang CL, Liu D, Nakano J, et al. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer. J Clin Oncol. 2005;23(34):8765-8773.
39. Ma L, Wang Y, Malbon CC, Wang HY. Dishevelled-3 C-terminal His single amino acid repeats are obligate for Wnt5a activation of non-canonical signaling. J Mol Signal. 2010;5:19.
40. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxford). 2012;204(1):17-33.
41. Whang YM, Jo U, Sung JS, et al. Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. PloS One. 2013;8(1):e53012.
42. Chiou GY, Cherng JY, Hsu HS, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012;159(2):240-250.
43. Huang Y, Liu G, Zhang B, Xu G, Xiong W, Yang H. Wnt-5a regulates proliferation in lung cancer cells. Oncol Rep. 2010;23(1):177-181.
44. Uysal-Onganer P, Kypta RM. Wnt11 in 2011-the regulation and function of a non-canonical Wnt. Acta Physiol (Oxford). 2012;204(1):52-64.
45. Prajerova I, Honsa P, Chvatal A, Anderova M. Distinct effects of sonic hedgehog and Wnt-7a on differentiation of neonatal neural stem/progenitor cells in vitro. Neuroscience. 2010;171(3):693-711.
46. Winn RA, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005;280(20):19625-19634.
47. Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PloS One. 2012;7(3):e32921.
48. Winn RA, Van Scoyk M, Hammond M, et al. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 2006;281(37):26943-26950.
49. Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA, Winn RA. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res. 2010;8(6):833-843.
50. Avasarala S, Van Scoyk M, Wang J, et al. hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression. Biol Open. 2013;2(7):675-685.
51. Heasley LE, Winn RA. Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells. Methods Mol Biol. 2008;468:187-196.
52. Hu Y, Galkin AV, Wu C, Reddy V, Su AI. CAFet al.gorithm reveals Wnt/PCP signature in lung squamous cell carcinoma. PloS One. 2011;6(10):e25807.
53. Ohira T, Gemmill RM, Ferguson K, et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA. 2003;100(18):10429-10434.
54. Kren L, Hermanova M, Goncharuk VN, et al. Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases. Cesk Patol. 2003;39(1):17-20.
55. Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res. 2007;13(20):6087-6092.
56. Fang X, Gu P, Zhou C, et al. Beta-catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells [published online ahead of print May 23, 2013]. Pulm Pharmacol Ther. 2013; doi:10.1016/j. pupt.2013.05.005.
57. Sidhu SS, Nawroth R, Retz M, Lemjabbar-Alaoui H, Dasari V, Basbaum C. EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesis. Oncogene. 2010;29(29):4145-4156.
58. Toyokawa G, Cho HS, Masuda K, et al. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia. 2011;13(10):887-898.
59. Han A, Song Z, Tong C, et al. Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008;583(1):26-31.
60. Hommura F, Furuuchi K, Yamazaki K, et al. Increased expression of betacatenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer. 2002;94(3):752-758.
61. Retera JM, Leers MP, Sulzer MA, Theunissen PH. The expression of betacatenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol. 1998;51(12):891-894.
62. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6(12):4789-4796.
63. Xu C, Xie D, Yu SC, et al. Beta-catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013;73(10):3181-3189.
64. Bleckmann A, Siam L, Klemm F, et al. Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta-catenin in cerebral metastasis of lung adenocarcinomas. Clin Exp Metastasis. 2013;30(4):471-482.
65. Ueda M, Gemmill RM, West J, et al. Mutations of the beta-and gammacatenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001;85(1):64-68.
66. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer. 2001;30(3):316-321.
67. Wang HQ, Xu ML, Ma J, Zhang Y, Xie CH. Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Comm. 2012;417(1):62-66.
68. Wei Q, Zhao Y, Yang ZQ, et al. Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression. Lung Cancer. 2008;62(2):181-192.
69. Zhao Y, Yang ZQ, Wang Y, et al. Dishevelled-1 and dishevelled-3 affect cell invasion mainly through canonical and noncanonical Wnt pathway, respectively, and associate with poor prognosis in nonsmall cell lung cancer. Mol Carcinogenesis. 2010;49(8):760-770.
70. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22(46):7218-7221.
71. Bartling B, Rehbein G, Simm A, Silber RE, Hofmann HS. Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma. Int J Oncol. 2010;36(4):1015-1021.
72. Chen Z, Li J, Li QS, et al. Suppression of PPN/MG61 attenuates Wnt/beta-catenin signaling pathway and induces apoptosis in human lung cancer. Oncogene. 2008;27(24):3483-3488.
73. Lum L, Clevers H. Cell biology. The unusual case of Porcupine. Science. 2012;337(6097):922-923.
74. Sun JZ, Yang XX, Hu NY, Li X, Li FX, Li M. Genetic variants in MMP9 and TCF2 contribute to susceptibility to lung cancer. Chin J Cancer Res 2011;23(3):183-187.
75. Xu HT, Wei Q, Liu Y, et al. Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Ann Surg Oncol. 2007;14(11):3251-3259.
76. Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138(1):51-62.
77. Liu Y, Dong QZ, Wang S, et al. Abnormal expression of Pygopus 2 correlates with a malignant phenotype in human lung cancer. BMC Cancer. 2013;13:346.
78. Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurrer MO. APC mutations are infrequent but present in human lung cancer. Cancer Lett. 2004;207(2):197-203.
79. Kanzaki H, Ouchida M, Hanafusa H, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med. 2006;18(2):279-284.
80. Busch AM, Johnson KC, Stan RV, et al. Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer. 2013;13:211.
81. Casas-Selves M, Kim J, Zhang Z, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012;72(16):4154-4164.
82. Zheng H, Saito H, Masuda S, Yang X, Takano Y. Phosphorylated GSK3beta-ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res. 2007;27(5B):3561-3569.
83. Gao Z, Xu Z, Hung MS, et al. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep. 2009;22(6):1479-1484.
84. Fukui T, Kondo M, Ito G, et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in nonsmall-cell lung cancer. Oncogene. 2005;24(41):6323-6327.
85. Lee AY, He B, You L, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene. 2004;23(39):6672-6676.
86. Tsuji T, Miyazaki M, Sakaguchi M, Inoue Y, Namba M. A REIC gene shows down-regulation in human immortalized cells and human tumorderived cell lines. Biochem Biophys Res Comm. 2000;268(1):20-24.
87. Kobayashi K, Ouchida M, Tsuji T, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene. 2002;282(1-2):151-158.
88. Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest. 2013;123(3):1241-1261.
89. Liu X, Zhang X, Zhan Q, Brock MV, Herman JG, Guo M. CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol Ther. 2012;13(12):1152-1157.
90. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. J Pathol. 2013;230(2):194-204.
91. Okamoto J, Hirata T, Chen Z, et al. EMX2 is epigenetically silenced and suppresses growth in human lung cancer. Oncogene. 2010;29(44):5969-5975.
92. Tan M, Wu J, Cai Y. Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Comm. 2013;438(4):673-679.
93. Zhang YW, Miao YF, Yi J, Geng J, Wang R, Chen LB. Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma. 2010;57(3):228-233.
94. Tang M, Torres-Lanzas J, Lopez-Rios F, Esteller M, Sanchez-Cespedes M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer. 2006;119(11):2603-2606.
95. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol. 2003;201(2):204-212.
96. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004;64(14):4717- 4720.
97. Korobko EV, Kalinichenko SV, Shepelev MV, et al. [Suppression of WIFI transcript and protein in non-small cell lung carcinomas]. Mol Gen Mikrobiol Virusol. 2007;(2):13-18.
98. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol. 2010;17(3):878-888.
99. Nozaki I, Tsuji T, Iijima O, et al.Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer.Int J Oncol. 2001. 19. 1.117-121
100. Na Y, Lee SM, Kim DS, Park JY. Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers. Cancer Biomark. 2012;12(2):73-79.
101. Zhu J, Wang Y, Duan J, et al. DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2012 (September 25);31:80.
102. Jang JS, Jeon HS, Sun Z, et al. Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012;18(13):3658-3667.
103. Xu HT, Li QC, Dai SD, Xie XM, Liu DI, Wang EH. The expression patterns and correlations of chibby, beta-catenin, and DNA methyltransferase-1 and their clinicopathological significance in lung cancers. APMIS. 2011;119(11):750-758.
104. Zhang S, Wang Y, Dai SD, Wang EH. Down-regulation of NKD1 increases the invasive potential of non-small-cell lung cancer and correlates with a poor prognosis. BMC Cancer. 2011;11:186.
105. Li X, Cai L, Liang M, Wang Y, Yang J, Zhao Y. ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec (Hoboken). 2008;291(5):593-600.
106. Yang LH, Xu HT, Li QC, et al. Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer. Tumour Biol. 2013;34(2):749-757.
107. Lv L, Wan C, Chen B, et al. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating Wnt signaling pathway [published online ahead of print July 31, 2013]. J Cell Biochem. 2013;doi:10.1002/jcb. 24635.
108. Pecina-Slaus N, Nikuseva Martic T, Zeljko M, Bulat S. Brain metastases exhibit gross deletions of the APC gene. Brain Tumor Pathol. 2011;28(3):223-228.
109. Hussain M, Rao M, Humphries AE, et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 2009;69(8):3570-3578.
110. Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells. 2013;36(1):69-73.
111. Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009;55(9):1656-1664.
112. Liu YL, Yang HP, Zhou XD, Gong L, Tang CL, Wang HJ. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 2011;11(9):1098-1110.
113. Kim J, You L, Xu Z, et al. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 2007;133(3):733-737.
114. Tsuji T, Nozaki I, Miyazaki M, et al. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Comm. 2001;289(1):257-263.
115. Jung IL, Kang HJ, Kim KC, Kim IG. Knockdown of the Dickkopf 3 gene induces apoptosis in a lung adenocarcinoma. Int J Mol Med. 2010;26(1):33-38.
116. Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001;152(1):87-96.
117. Yuan D, Liu L, Gu D. Transcriptional regulation of livin by betacatenin/TCF signaling in human lung cancer cell lines. Mol Cell Biochem. 2007;306(1-2):171-178.
118. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in nonsmall-cell lung cancer cell. PloS One. 2013;8(5):e65309.
119. Gao Y, Liu Z, Zhang X, et al. Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett. 2013;336(1):231-239.
120. Zhao J, Ma MZ, Ren H, et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin Cancer Res. 2013;19(13):3567-3576.
121. Lee SB, Gong YD, Park YI, Dong MS. 2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells. Biochem Biophys Res Comm. 2013;431(4):746-752.
122. Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006;11(6):687-692.
123. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012; 4(5):a008052.
124. Garber K. Drugging the Wnt pathway: problems and progress. J Natl Cancer Inst. 2009;101(8):548-550.
125. Watanabe K, Dai X. Winning WNT: race to Wnt signaling inhibitors. Proc Natl Acad Sci USA. 2011;108(15):5929-5930.
126. Gurney A, Axelrod F, Bond CJ, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA. 2012;109(29):11717-11722.
127. Hitt E. Wnt signaling inhibition: will decades of effort be fruitful at last? OncLive. 2013 http://www.onclive.com/publications/oncology-live/2012/ december-2012/Wnt-Signaling-Inhibition-Will-Decades-of-Effort-Be-Fruitful-at- Last. Accessed November 14, 2013.
128. El-Khoueiry AB, Ning Y, Yang D, et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol. 2013;31(Suppl):abstract 2501.
129. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614-620.
130. Waaler J, Machon O, Tumova L, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 2012;72(11): 2822-2832.
131. Lau T, Chan E, Callow M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013;73(10):3132-3144.
132. Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013;110(31):12649-12654.
133. Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer. 2013;13:193.
134. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2?-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anti-Cancer Drugs. 1997;8(4):358-368.
135. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Disc. 2011;1(7):598-607.
136. Stewart DJ, Nunez MI, Jelinek J, et al. Decitabine effect on human tumor expression of various transporters. Proc Am Soc Clin Oncol. 2009;27(15S):ab stract 2540.
137. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15(11):3881-3888.
138. Lu C, Stewart DJ, Lee JJ, et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PloS One. 2012;7(4) e34833.